Articles
February 23, 2021
Rare Disease Day 2021: Rare Is Many. Rare Is Strong. Rare Is Proud.
While some aspects of living with a rare disease are similar, there is no singular shared experience. There is, however, a common sentiment among those...
Read More ›
February 15, 2021
Recapping Alnylam's 2020 DE&I Speaker Series
Launched in 2019, the DE&I Speaker Series welcomes external speakers to Alnylam to share their experiences and perspectives on different topics related to...
Read More ›
February 6, 2021
Alnylam Named to Bloomberg's 2021 Gender-Equality Index
Alnylam has been selected to Bloomberg's Gender-Equality Index for 2021
Read More ›
December 7, 2020
Alnylam Publishes Its 1st-Ever Rare Disease Trend Report
Alnylam's 2020 Rare Disease Trend Report features findings from interviews with 30 U.S. payer and plan decision-makers about barriers to orphan drug access.
Read More ›
December 7, 2020
Alnylam Releases 2nd Annual Patient Access Philosophy Report
The 2020 Alnylam Patient Access Philosophy Report details Alnylam's progress against key metrics related to patient access to its innovative RNAi therapeutics.
Read More ›
November 20, 2020
6 in a Row! Alnylam Named a Boston Globe Top Place to Work for 2020
Alnylam has been named to The Boston Globe's Top Places to Work list for 2020, marking 6th years in a row.
Read More ›
October 29, 2020
Alnylam Named a Science Magazine Top Employer for 2nd Year in a Row
Alnylam has been named to Science Magazine and Science Career's Top Employers list for the second year in a row.
Read More ›
October 1, 2020
A New European Biotech Social Pact
The European Pact builds on Alnylam’s own pledge, encouraging biotech companies to be a force for good in partnering with European authorities, citizens and...
Read More ›
September 14, 2020
Navigating AHP and Pain During a Pandemic
As the COVID-19 pandemic continues to have a significant impact on people and communities around the world, it poses unique challenges for people living with...
Read More ›
September 2, 2020
With Innovation in Market Access, European Patients Can Fully Experience Biotech’s Transfo ...
What’s needed is a larger measure of creativity, flexibility and coordination around market access. This must become the new baseline environment in which...
Read More ›
